Clinical Trial Update: 9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY) [Phase 1]

View source ↗

Summary

This Phase 1 clinical trial update describes a study of 9-ING-41 combined with retifanlimab and a modified FOLFIRINOX regimen in patients with advanced pancreat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• 9-ING-41
• Modified FOLFIRINOX (modified FOLFIRINOX)
• Retifanlimab (retifanlimab)

Snippet

Sponsor: Anwaar Saeed | Conditions: Pancreatic Adenocarcinoma | Phase 1 | Status: RECRUITING